Syracuse Bio Campus: Early Stage Capability From Sequence To IND And Beyond

Moving from a genetic sequence to regulatory filings requires a smooth, well-coordinated plan. This document breaks down the early-stage capabilities at a specialized bio campus designed to move biopharmaceutical projects forward quickly and safely. Backed by more than 30 years of combined CDMO experience, the team uses science-driven, phase-appropriate development to lower risks right from the start. The facility is built for flexibility, working with multiple cell lines—like CHO-GS and NSO —and handling complex modalities including bispecifics and fusion proteins.

On-site services cover everything from mammalian process development to bioconjugation. To ensure seamless scaling and tech transfers, the campus features dedicated cell banking suites with vapor-phase liquid nitrogen storage alongside multiple inoculum suites. Rounding out these services are full in-house analytical capabilities that support method development, validation, and testing throughout the entire product lifecycle.